2,106 results on '"Kuo, Hann‐Chorng"'
Search Results
252. Comparison of the Therapeutic Effects of Urethral Injections of 50 and 100 Units of Botulinum A Toxin for Voiding Dysfunction
253. Videourodynamic Analysis of Pathophysiology of Men with Both Storage and Voiding Lower Urinary Tract Symptoms
254. Recovery of Detrusor Function After Urethral Botulinum A Toxin Injection in Patients with Idiopathic Low Detrusor Contractility and Voiding Dysfunction
255. Causes of Failed Urethral Botulinum Toxin A Treatment for Emptying Failure
256. Intravesical Botulinum Toxin A Injections Plus Hydrodistension Can Reduce Nerve Growth Factor Production and Control Bladder Pain in Interstitial Cystitis
257. Urothelial Dysfunction and Chronic Inflammation are Associated With Increased Bladder Sensation in Patients With Chronic Renal Insufficiency
258. Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes among Patients with Interstitial Cystitis/Bladder Pain Syndrome: An Investigation of the European Society for the Study of Interstitial Cystitis Histopathological Classification
259. Videourodynamic precision diagnosis and treatment of lower urinary tract symptoms in women
260. Ultrastructural changes in the underactive bladder
261. Recurrent urinary tract infection in women and overactive bladder – Is there a relationship?
262. A step toward precision diagnosis of interstitial cystitis
263. Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
264. Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction
265. Urothelial health after platelet‐rich plasma injection in intractable recurrent urinary tract infection: Improved cell proliferation, cytoskeleton, and barrier function protein expression
266. Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions in patients with recurrent and persistent urinary tract infections
267. Increased Risk of Large Post-Void Residual Urine and Decreased Long-Term Success Rate After Intravesical OnabotulinumtoxinA Injection for Refractory Idiopathic Detrusor Overactivity
268. REPEAT ONABOTULINUMTOXINA INJECTIONS PROVIDE BETTER THERAPEUTIC RESULTS THAN SINGLE INJECTION IN TREATMENT OF PAINFUL BLADDER SYNDROME: 1851
269. CAN AUTONOMIC DYSREFLEXIA IMPROVE AFTER DETRUSOR ONABOTULINUMTOXIN A INJECTIONS IN PATIENTS WITH CHRONIC SPINAL CORD INJURIES?: 1713
270. Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome
271. Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: A comparative randomized assessment of different regimens
272. Lower Urinary Tract Symptoms and Video-Urodynamic Characteristics of Women with Clinically Unsuspected Bladder Outlet Obstruction
273. Botulinum toxin injection for lower urinary tract dysfunction
274. MP23-04 BLADDER NECK INCOMPETENCE AS A POTENTIAL ETIOLOGY OF OVERACTIVE BLADDER SYNDROME IN WOMEN WITH STRESS URINARY INCONTINENCE AFTER ANTI-INCONTINENCE SURGERY—INSIGHTS FROM TRANSRECTAL SONOGRAPHY.
275. Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type 2 diabetes mellitus
276. Diagnostic and prognostic value of urine biomarkers among women with dysfunctional voiding.
277. Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome—A Comparative Study of Different Injection Number, Additives and Concentrations.
278. The Efficacy and Mid-term Durability of Urethral Sphincter Injections of Platelet-Rich Plasma in Treatment of Female Stress Urinary Incontinence.
279. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?
280. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions
281. BASELINE URODYNAMIC PARAMETERS DO NOT AFFECT THE TREATMENT OUTCOME OF INTRAVESICAL 100U ONABOTULINUMTOXINA INJECTION FOR PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY: 2314
282. A GREATER URETHRAL RESISTANCE INDEX INDICATES ANATOMICAL BLADDER OUTLET OBSTRUCTION IN WOMEN WITH VOIDING DYSFUNCTION: 2309
283. PREDICTIVE FACTORS FOR SUCCESSFUL ONABOTULINUMTOXINA INJECTIONS FOR REFRACTORY INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME: 1552
284. Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome
285. Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity
286. Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome
287. Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome
288. Urinary nerve growth factor in women with overactive bladder syndrome
289. Will detrusor acontractility recover after medical or surgical treatment? A longitudinal long‐term urodynamic follow‐up
290. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis
291. A double‐blind, randomized, placebo‐controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan
292. Botulinum toxin A injection in the treatment of chronic pelvic pain with hypertonic pelvic floor in women: Treatment techniques and results
293. Obstructive patterns in videourodynamic studies predict responses of female dysfunctional voiding treated with or without urethral botulinum toxin injection: a long-term follow-up study
294. Botulinum Toxin Paves the Way for the Treatment of Functional Lower Urinary Tract Dysfunction
295. Female bladder neck dysfunction—A video‐urodynamic diagnosis among women with voiding dysfunction
296. Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics
297. Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome—A prospective, multicenter, randomized, double‐blind, placebo‐controlled study
298. Clinical guidelines for interstitial cystitis/bladder pain syndrome
299. PD24-07 PREDICTIVE FACTORS FOR A SUCCESSFUL TREATMENT OUTCOME OF INTRAVESICAL BOTULINUM TOXIN A INJECTION FOR PATIENTS WITH INTERSTITIAL CYSTITIS/ BLADDER PAIN SYNDROME
300. MP77-07 IMPROVEMENT OF CELL PROLIFERATION, CYTOSKELETON AND BARRIER FUNCTION PROTEIN EXPRESSION AFTER PLATELET-RICH PLASMA INJECTION SUGGEST IMPROVED UROTHELIUM HEALTH IN THE PATIENTS WITH INTRACTABLE RECURRENT URINARY TRACT INFECTION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.